?A clinical trial to evaluate safety and tolerability of VICHREPOL, carrying chimeric recombinant protein rec(24-41); comprises C-terminal p17, full p24, immunoreactive fragment of gp4 with polyoxidonium adjuvant

Trial Details:

I Completed
Moscow Institute of Immunology, Russian Federation, Russian Federation Ministry of Education and Science March 01, 2006
Vichrepol Env, gag B
Vichrepol Protein
polyoxidonium adjuvant
Russian Federation 15